Pembrolizumab administration shown to not increase oral cavity surgery complications

A University of Cincinnati study found administering an immunotherapy drug before surgery for oral cavity cancer did not lead to increased rates of complications during and after surgery.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup